Atlas Trials

A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.

Clinical trial NCT04742413 · TERMINATED

Trial details

NCT number
NCT04742413
Sponsor
Angelini Farmacéutica
Status
TERMINATED
Study type
OBSERVATIONAL
Schizophrenia
Start date
2020-12-29
Primary completion
2022-02-15
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.